检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]合肥市安徽医科大学第一附属医院感染病科,230022
出 处:《实用肝脏病杂志》2011年第3期183-184,共2页Journal of Practical Hepatology
基 金:国家973计划前期研究专项课题基金(2009CB526411);国家自然科学基金(30771907);安徽省高校自然科学基金(KJ2008B300)
摘 要:目的观察恩替卡韦治疗CHB患者的疗效。方法 43例HBeAg阳性和18例HBeAg阴性患者接受恩替卡韦治疗,比较两组治疗24周和48周时的疗效。结果在治疗24周时,HBeAg阳性组HBV DNA转阴15例(34.9%)4,8周时转阴28例(65.1%),而HBeAg阴性组分别转阴15例(83.3%)和17例(94.4%,P=0.001和0.018);两组在24周和48周时ALT复常率均无显著性差异(P=0.713和0.138);在34例HBV DNA定量>107copies/ml与27例HBV DNA定量<107copies/ml两组中,治疗24周时,HBV DNA转阴例数分别为11例(32%)和19例(70%,P=0.03),治疗48周时,则分别为23例(68%)和22例(81%,P=0.22)。结论本研究提示恩替卡韦治疗CHB有很好的抗病毒活性。Objective To evaluate the efficacy of entecavir in the treatment of patients with chronic hepatitis B.Methods 43 patients with HBeAg positive and 18 with HBeAg negative were treated with entecavir for 48 weeks.Results The HBV DNA negative rates in the HBeAg negative group were 83.3% and 94.4%,higher than 34.9% and 65.1% in the HBeAg positive group at week 24 and week 48(P=0.001 and 0.018,respectively),while the ALT normalization rates between the two groups had no significant difference(P=0.713 and 0.138);in 34 patients with serum HBV DNA1×107 copies/ml and 27 with serum HBV DNA〈1×10^7copies/ml,the HBV DNA negative rates at week 24 were 32% and 70%,respectively(P=0.03),while those at week 48 were 68% and 81%,respectively(P=0.22).Conclusions Entecavir has significant anti-viral activity in the treatment of patients with CHB.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.63